Articaine

Identification

Name
Articaine
Accession Number
DB09009
Description

Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 284.374
Monoisotopic: 284.119463206
Chemical Formula
C13H20N2O3S
Synonyms
  • Articaína
  • Articaine
  • Articainum
External IDs
  • HOE 045

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Articaine.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Articaine.
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Articaine.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Articaine.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Articaine.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Articaine.
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Articaine.
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Articaine.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Articaine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Articaine hydrochlorideQS9014Q79223964-57-0GDWDBGSWGNEMGJ-UHFFFAOYSA-N
International/Other Brands
Septanest / Septocaine / Ultracaine
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.005 mg)SolutionInfiltrationDentsply Pharmaceutical1997-02-262003-11-28Canada
4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.005 mg)SolutionInfiltrationDentsply Pharmaceutical2004-01-29Not applicableCanada
4% Astracaine Dental With Epinephrine Forte 1:100,000 (0.01mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.01 mg)SolutionInfiltrationDentsply Pharmaceutical1997-02-262003-11-28Canada
4% Astracaine Dental With Epinephrine Forte 1:100,000 (0.01mg/ml)Articaine hydrochloride (40 mg) + Epinephrine (0.01 mg)SolutionInfiltrationDentsply Pharmaceutical2004-01-29Not applicableCanada
ArticadentArticaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.01 mg/1mL)Injection, solutionSubcutaneousDentsply Pharmaceutical2000-04-03Not applicableUs
ArticadentArticaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.005 mg/1mL)Injection, solutionSubcutaneousDentsply Pharmaceutical2000-04-03Not applicableUs
ArticaineArticaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.005 mg/1mL)Injection, solutionSubcutaneousNDC, Inc.2015-12-04Not applicableUs
ArticaineArticaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.005 mg/1mL)Injection, solutionSubcutaneousPatterson Dental2014-12-22Not applicableUs
ArticaineArticaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.01 mg/1mL)Injection, solutionSubcutaneousDarby Dental Supply Llc2017-03-012018-01-02Us
ArticaineArticaine hydrochloride (40 mg/1mL) + Epinephrine bitartrate (0.01 mg/1mL)Injection, solutionSubcutaneousNDC, Inc.2015-06-22Not applicableUs

Categories

ATC Codes
N01BB58 — Articaine, combinationsN01BB08 — Articaine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as thiophene carboxylic acids and derivatives. These are compounds containing a thiophene ring which bears a carboxylic acid group (or a salt/ester thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiophenes
Sub Class
Thiophene carboxylic acids and derivatives
Direct Parent
Thiophene carboxylic acids and derivatives
Alternative Parents
Methyl esters / Heteroaromatic compounds / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Dialkylamines / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
Amine / Amino acid or derivatives / Aromatic heteromonocyclic compound / Carboximidic acid / Carboximidic acid derivative / Carboxylic acid derivative / Carboxylic acid ester / Heteroaromatic compound / Hydrocarbon derivative / Methyl ester
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
D3SQ406G9X
CAS number
23964-58-1
InChI Key
QTGIAADRBBLJGA-UHFFFAOYSA-N
InChI
InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)
IUPAC Name
methyl 4-methyl-3-[2-(propylamino)propanamido]thiophene-2-carboxylate
SMILES
CCCNC(C)C(=O)NC1=C(SC=C1C)C(=O)OC

References

Synthesis Reference

U.S. Patent 3,910,924.

General References
Not Available
KEGG Drug
D07468
PubChem Compound
32170
PubChem Substance
310264968
ChemSpider
29837
BindingDB
50225496
RxNav
592464
ChEBI
91834
ChEMBL
CHEMBL1093
Drugs.com
Drugs.com Drug Page
Wikipedia
Articaine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentAnesthesia Complications / Anesthesia Morbidity / Dental Implant Failed / Surgical Complications From Local Anesthesia1
4CompletedHealth Services ResearchAdverse Reaction to Other Local Anesthetics / Impacted Third Molar Tooth1
4CompletedOtherPeriodontitis1
4CompletedPreventionAnesthesia of Mucous Membrane1
4CompletedSupportive CarePain1
4CompletedTreatmentDental Extraction / Maxillary Teeth / Overcoming the Failure of Anaesthesia1
4CompletedTreatmentGastroscopy1
4CompletedTreatmentIrreversible Pulpitis1
4CompletedTreatmentIrreversible Pulpitis / Pain1
4CompletedTreatmentLocal Anesthesia of the Skin3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionDental72 mg
InjectionSubmucosal
Injection, solutionDental; Infiltration
SolutionDental0.006 mg/ml
SolutionDental0.012 mg/ml
InjectionDental40 mg
Injection40 mg/mL
SolutionInfiltration0.009 mg
LiquidInfiltration
SolutionDental0.018 mg
Injection, solutionSubcutaneous
Injection, solutionSubmucosal
SolutionInfiltration
Injection80 mg/2mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)172-173U.S. Patent 3,910,924.
Predicted Properties
PropertyValueSource
Water Solubility0.0285 mg/mLALOGPS
logP1.93ALOGPS
logP3.25ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.61ChemAxon
pKa (Strongest Basic)8.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.43 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity76.78 m3·mol-1ChemAxon
Polarizability30.54 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 20, 2014 11:45 / Updated on June 12, 2020 11:42

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates